The paper this week is the OPRD synthesis of Ubrogepant, the first drub approved by the FDA for migraines as they’re currently happening, rather than as a preventative measure. Main paper: https://pubs.acs.org/doi/10.1021/acs.oprd.7b00293
A couple supporting papers if interested: https://www.nejm.org/doi/full/10.1056/NEJMoa1813049 and https://www.nature.com/articles/s41582-018-0003-1.
